Liquidia Corporation (LQDA)

Liquidia Corp.'s stock has been impacted by the Q2 2025 financial results and YUTREPIA launch, analyst ratings and price targets, insider trading activity, the upcoming Q3 2025 financial results, clinical data presentations, and stock performance. YUTREPIA achieved over 900 unique patient prescriptions and 550 patient starts within 11 weeks of FDA approval. Several Wall Street analysts have reiterated "Buy" ratings and raised price targets for LQDA. There has been notable insider selling activity. The company presented positive interim data from its ASCENT trial for PH-ILD patients. The stock has shown significant growth, with a 69.09% increase over the past six months and a 103.76% increase over the last year as of August 2025.

Product demand for biopharmaceutical companies like Liquidia, particularly those focused on rare diseases such as pulmonary hypertension, is generally driven by factors like disease prevalence, diagnosis rates, and the efficacy and accessibility of treatments, rather than typical seasonal fluctuations. There is no specific information indicating significant demand seasonality for Liquidia's products. The strong initial demand for YUTREPIA following its launch suggests a consistent need for innovative treatments in its target patient population.

Liquidia Corp. is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for unmet medical needs, particularly in rare cardiopulmonary diseases. It operates within the Health Care sector, specifically in the Biotechnology: Pharmaceutical Preparations industry, and uses its PRINT® technology to produce uniform drug particles. Its major products include YUTREPIA™ (treprostinil) inhalation powder, Remodulin, L606, and Generic Treprostinil Injection.

Liquidia Corporation primarily develops, manufactures, and commercializes its products for unmet patient needs in the United States. While it plans to pursue regulatory filings in major markets and its stock is traded on several European exchanges, its direct operational footprint outside the U.S. is not extensively detailed.

Liquidia's brand reputation appears to be generally positive, particularly in the context of its product development and commercialization efforts. The company's news sentiment score is similar to the average for Medical companies, and there hasn't been a significant change in news mentions in the last month. The successful FDA approval and commercial launch of YUTREPIA, along with positive clinical data presentations, have likely contributed to a favorable public perception and investor confidence. Analyst ratings predominantly lean towards "Moderate Buy," further indicating a positive outlook from the financial community.

Liquidia Corporation has a significant institutional ownership presence. As of June 30, 2025, 309 institutional owners and shareholders held a total of 61,484,796 shares. Major institutional owners include Caligan Partners LP, BlackRock, Inc., Farallon Capital Management LLC, Vanguard Group Inc, and Goldman Sachs Group Inc. Institutional investors collectively own over 50% of the company. Hedge funds own approximately 17% of Liquidia shares. Insider ownership is also notable, with insiders owning a significant proportion of the company's shares, including CEO Roger Jeffs who owns 2.5% of the company's shares. The general public holds a 14% stake in Liquidia.